PSNL News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

PS

Mkt Cap

$1.67B

Volume

3.19M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.GlobeNewswire Inc. · Sep 23, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).GlobeNewswire Inc. · Sep 3, 2026

Why Tempus AI Skyrocketed This WeekTempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.The Motley Fool · Aug 23, 2026

PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AILaw firm Wohl & Fruchter is investigating whether the Personalis board acted in shareholders' best interests regarding the proposed $16.25 per share sale to Tempus AI. Since the announcement on July 20, 2026, Personalis shares have fallen approximately 14% due to the deal's partial stock consideration and Tempus share price decline. Shareholders have expressed disappointment with the transaction.GlobeNewswire Inc. · Aug 4, 2026

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to TempusLaw firm Julie & Holleman is investigating Personalis' proposed acquisition by Tempus AI for $16.25 per share, raising concerns about fair value and potential conflicts of interest given Tempus' existing significant equity stake and strategic partnership with Personalis since 2023.GlobeNewswire Inc. · Aug 3, 2026

Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares?Tempus AI CEO Eric Lefkofsky sold 250,000 shares worth $10.5 million on July 28, 2026, reducing his stake by 4% through a pre-scheduled trading plan established in March. Despite the sale, Lefkofsky retains approximately 6.5 million shares. The article suggests this represents routine portfolio management rather than a loss of confidence, noting the company's strong Q2 2026 performance with 20% YoY revenue growth and 31% oncology volume growth, plus a strategic $1.5 billion acquisition of Personalis.The Motley Fool · Jul 31, 2026

Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating several companies for potential securities law violations and breaches of fiduciary duties related to proposed acquisitions. The investigations focus on whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests. The firm is seeking increased consideration, additional disclosures, and other relief on behalf of affected shareholders.GlobeNewswire Inc. · Jul 30, 2026

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to TempusJulie & Holleman LLP is investigating Personalis Inc.'s proposed acquisition by Tempus AI for $16.25 per share. The law firm is concerned about potential conflicts of interest given Tempus' existing significant equity stake and strategic relationship with Personalis since 2023, and whether shareholders are receiving fair value for their shares.GlobeNewswire Inc. · Jul 20, 2026

Personalis (PSNL) Q2 Revenue Falls 24%Personalis reported Q2 2025 financial results with revenue falling 24% year-over-year to $17.2 million, missing estimates. Despite financial challenges, the company saw a 59% increase in clinical test volumes for its NeXT Personal platform, with promising cancer detection research.The Motley Fool · Aug 6, 2025

From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in MedicineAI is transforming healthcare with projected market growth exceeding $110 billion by 2030, enabling advanced diagnostic tools, early disease detection, and more efficient medical research across multiple sectors.Benzinga · Jul 16, 2025

PS

PSNLPersonalis, Inc. Common Stock

PSNL

Pay with—

Available Balance0.00

Your PositionYou don't own any PSNL yet.

Related Tickers

Earnings